Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a specialty pharmaceutical company that focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company’s product candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. For more information, visit the company’s website at www.zynerba.com.
About CBDWire
CBDWire (CBDW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, CBDW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information, visit https://www.cbdwire.com
Please see full disclaimers on the CBDWire website: http://nnw.fm/Disclaimer
CBDWire (CBDW)
Denver, CO
cbdwire.com
303.498.7722 Office
[email protected]
